Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and Older

6 november 2026 uppdaterad av: Ab&B Bio-tech Co., Ltd.JS

A Post-Marketing, Open-Label, Single-Arm Observational Study to Evaluate the Safety and Vaccination Influencing Factors of Subunit Influenza Vaccine in Individuals Aged 6 Months and Older

This is a post-marketing, prospective observational study to evaluate the safety of a subunit influenza vaccine and the factors influencing influenza vaccination in individuals aged 6 months and older. A total of 7,000 vaccinated participants will be divided into Subgroup A (1,000 participants, active surveillance) and Subgroup B (6,000 participants, passive surveillance), and monitored for adverse events and serious adverse events within 28 days after vaccination. Participants in Subgroup A will additionally complete an electronic questionnaire on their knowledge of influenza and factors influencing their vaccination decisions.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

Study Objectives The primary objectives of this study are: (1) to evaluate the safety of the subunit influenza vaccine in individuals aged 6 months and older after vaccination, in order to assess the occurrence of adverse reactions; and (2) to investigate vaccinated individuals' knowledge of influenza and influenza vaccine, and the factors influencing their vaccination decisions.Study Design This is a post-marketing, prospective, open-label, single-arm observational study. Participants who have already received the subunit influenza vaccine at the study site will be enrolled and divided into two subgroups according to the surveillance mode: Subgroup A (1,000 participants) under active surveillance, and Subgroup B (6,000 participants) under passive surveillance. All participants will be observed for 30 minutes after vaccination and monitored for adverse events (AEs) and serious adverse events (SAEs) within 28 days after vaccination.Study Population Individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and are able to comply with the study requirements. Participants with allergy to any vaccine component (including excipients, formaldehyde, or Triton N-101), acute illness, severe chronic disease, acute exacerbation of chronic disease, fever, uncontrolled epilepsy, other progressive neurological diseases, a history of Guillain-Barré syndrome, or a history of severe adverse reactions to previous influenza vaccination will be excluded.Safety Monitoring All participants will remain under observation for 30 minutes immediately after vaccination. The occurrence of AEs and SAEs within 28 days post-vaccination will be collected and recorded, including solicited local reactions (pain, swelling, erythema, pruritus, induration, ecchymosis) and systemic events (fever, cough, headache, rhinorrhea, fatigue, myalgia, arthralgia, gastrointestinal symptoms, rash, etc.). Subgroup A participants will receive a telephone follow-up on Day 28, while Subgroup B participants will self-report AEs to investigators during the same period. Any SAE will be reported in accordance with applicable regulations.Influencing Factor Survey Participants in Subgroup A will complete an electronic questionnaire during the post-vaccination observation period (by themselves if aged 18 years or older, or by their guardians if under 18), collecting demographic information, medical and vaccination history, and their knowledge of influenza and influenza vaccine, as well as the factors influencing their vaccination decisions.

Studietyp

Observationell

Inskrivning (Beräknad)

7000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Jiangxi
      • Ganzhou, Jiangxi, Kina
        • Rekrytering
        • Ganzhou Center for Disease Control and Prevention (Ganzhou Health Comprehensive Supervision and Law Enforcement Bureau)
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

6 månader och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Healthy individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and meet the eligibility criteria.

Beskrivning

Inclusion Criteria:

  1. Aged 6 months and older;
  2. Have received the subunit influenza vaccine at the study site;
  3. Able to comply with the requirements of the study protocol

Exclusion Criteria:

  1. Allergy to any component of the vaccine, including excipients, formaldehyde, or the splitting agent Triton N-101;
  2. Acute illness, severe chronic disease, acute exacerbation of chronic disease, or fever;
  3. Uncontrolled epilepsy or other progressive neurological diseases, or a history of Guillain-Barré syndrome;
  4. History of severe adverse reactions following previous influenza vaccination;
  5. Any other condition deemed by the investigator to be unsuitable for enrollment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Group A

Active Surveillance Group

Participants will receive one dose of Subunit Influenza Vaccine

Group B

Passive Surveillance Group

Participants will receive one dose of Subunit Influenza Vaccine

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Occurrence of AEs and ADRs
Tidsram: Within 28 days post-vaccination

Adverse events and adverse drug reactions occurring within 28 days of vaccination will be recorded, including solicited local and systemic reactions.

Within 28 days post-vaccination
Occurrence of SAEs
Tidsram: Within 28 days post-vaccination

Serious adverse events occurring within 28 days of vaccination will be recorded.

Within 28 days post-vaccination

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

4 september 2026

Primärt slutförande (Beräknad)

31 mars 2027

Avslutad studie (Beräknad)

30 september 2027

Studieregistreringsdatum

Först inskickad

6 november 2026

Först inskickad som uppfyllde QC-kriterierna

6 november 2026

Första postat (Faktisk)

12 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera